NASDAQ:BLUE
bluebird bio Stock News
$1.03
-0.0200 (-1.90%)
At Close: May 17, 2024
5 Under-the-Radar Tickers That Will Stomp the Market in 2021
06:32am, Thursday, 19'th Nov 2020
Investors are hyper-focused on COVID-19 right now, but once vaccines for the virus have been approved, other healthcare stocks will start to zoom forward.
SHAREHOLDER ALERT: Investigation of bluebird Announced by Holzer & Holzer, LLC
10:04am, Wednesday, 11'th Nov 2020
Atlanta, Georgia--(Newsfile Corp. - November 11, 2020) - Holzer & Holzer, LLC is investigating whether bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE) complied with federal securities
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, Inc. - BLUE
09:29pm, Tuesday, 10'th Nov 2020
NEW YORK, Nov. 10, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE). Such investors are advised to c
bluebird bio Announces November Investor Events
08:00am, Tuesday, 10'th Nov 2020
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences: Cowen 2020 IO
Can bluebird bio Recover From Another Major Setback?
06:23am, Friday, 06'th Nov 2020
Another manufacturing issue set the biotech's sickle cell disease program back much further than investors had hoped.
Here's Why Bluebird's Shares Fell Out of the Nest Today
02:27pm, Thursday, 05'th Nov 2020
A delay in submitting its sickle cell treatment to the FDA will push back a major source of future revenue.
Bluebird bio's stock plunges after submission delay of sickle cell disease treatment
10:11am, Thursday, 05'th Nov 2020
Shares of Bluebird bio Inc. traded 15.1% into the red in morning trading Thursday, after the gene therapy company pushed back the U.S. submission for approval of its sickle cell disease treatment Lent
Gene Therapy Stock Plunges On Unexpected Delay For Sickle Cell Drug
09:36am, Thursday, 05'th Nov 2020
Bluebird Bio announced a delay for a gene therapy in treating sickle cell disease, leading BLUE stock to tumble early Thursday. Now, the company expects to ask for approval in late 2022.
Were These Hedge Funds Wrong About Buying bluebird bio Inc (BLUE)?
09:08am, Tuesday, 03'rd Nov 2020
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in
7 Cutting-Edge Biotech Stocks for Tomorrow
08:59am, Wednesday, 28'th Oct 2020
Biotech stocks are always going to be here, in good times and bad. Let's look at a few that are worth considering on the long side.
bluebird bio to present new data from clinical studies of elivaldogene autotemcel (eli-cel, Lenti-D™) gene therapy at the 46th EBMT Annual Meeting.
Genomic Medicine: Summer 2020 Update
09:36am, Thursday, 13'th Aug 2020
FDA approvals, new guidance statements, and RMAT requests all show the pace of genomics is accelerating.
Companies Like bluebird bio (NASDAQ:BLUE) Are In A Position To Invest In Growth
11:22am, Wednesday, 12'th Aug 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
bluebird bio Appoints Denice Torres to Board of Directors
11:01am, Tuesday, 11'th Aug 2020
bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has appointed Denice Torres to its Board of Directors.
Global Hemoglobinopathy Treatment Drugs Market to Surpass US$ 6.4 Billion by 2027, Says Coherent Market Insights
12:00am, Tuesday, 11'th Aug 2020
The global hemoglobinopathy treatment drugs market is projected to exhibit a CAGR of 8.4% during the forecast period (2020-2027).
